The EAN, with the support of the Co-Chairs of the EAN Scientific Panel on Dementia and Cognitive Disorders, Prof. Sebastiaan Engelborghs and Prof. Massimo Filippi, and the Co-Chairs of the EAN Scientific Panel on Neuroimaging, Prof. Cristina Granziera and Dr Jacopo Paquini, is proud to announce the endorsement of the European Association of Nuclear Medicine (EANM) consensus paper on the role of molecular imaging and fluid biomarkers in diagnosis, treatment eligibility, and monitoring in Alzheimer’s disease.
The paper, resulting from the EANM Focus Meeting 7, provides an integrated framework for diagnosing Alzheimer’s disease (AD) based on biomarkers, determining treatment eligibility, and monitoring progress. It highlights the complementary roles of plasma and CSF biomarkers, as well as amyloid and tau PET scans, and identifies key priorities for future research.
The EANM Focus Meeting 7, which took place on 5 February 2026, aimed to reach multidisciplinary expert consensus on the appropriate clinical integration of molecular imaging and fluid biomarkers across the diagnostic, therapeutic, and preventive spectrum of AD, and to identify research priorities required to strengthen that evidence base of fluid and imaging biomarkers in the AD field. The meeting was attended by Prof. Paul Boon, EAN Brain Health Mission Steering Committee Co-Chair, who is a co-author of the paper together with other renowned experts.
The EANM Focus meeting 7 used a consensus process: (1) a systematic review of systematic reviews and meta-analyses (2020-2025), appraised using AMSTAR; (2) a two-round modified Delphi survey involving 33 multidisciplinary experts, rating 143 statements using a nine-point Likert scale, analysed using the RAND/UCLA Appropriateness Method; (3) a face-to-face consensus meeting (Palma de Majorca, February 2026).
The consensus, grounded in a clinico-biological approach, provides a structured, evidence-informed framework for integrating molecular imaging and fluid biomarkers across the diagnostic, therapeutic, and preventative continuum of AD. These findings collectively define an integrated biomarker framework for AD, while highlighting key priorities for future research: establishment of validated Centiloid thresholds for treatment decisions; harmonisation of biomarker platforms and reference standards across centres; development of longitudinal monitoring protocols for anti-amyloid therapy; construction of stage-specific clinical algorithms that incorporate co-pathology assessment; and evidence-based prevention programmes integrating biomarkers.
The EAN is pleased to endorse the consensus paper and support continued efforts towards harmonising the clinical use of biomarkers in Alzheimer’s disease across Europe.
Click here to read the paper: European Association of Nuclear Medicine (EANM) Focus Meeting 7: Consensus on the role of molecular imaging and fluid biomarkers in diagnosis, treatment eligibility, and monitoring in Alzheimer’s Disease – ScienceDirect
